- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Monitoring Immunotherapy Toxicities in CSCC and BCC
Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.
EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
EP: 2.Immunotherapy Landscape in cSCC and BCC
EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC
EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC
EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management
EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations
EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC
EP: 9.Staging Disease and Risk Stratification in CSCC and BCC
EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC
EP: 11.Socioeconomic Implications of CSCC and BCC
EP: 12.Immunosuppression in CSCC and BCC Treatment
EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers
EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Barker stated that while radiation toxicities can mimic immunotherapy adverse effects, a large analysis did not find radiotherapy increased immune-related adverse event rates when given within 90 days of immunotherapy initiation. Thus, adverse effects likely represent an additive effect of the 2 modalities rather than synergy. He emphasized the importance of continual cross-disciplinary communication to best attribute causality. Patel advised community providers using immunotherapy to have referral networks in place to manage unfamiliar toxicities. Hamid discussed engaging multidisciplinary care early for recurrent or aggressive skin cancers needing complex resection. Pisano described high-risk features that should trigger medical oncology referral, including rapidly enlarging/painful lesions, multiple in-transit metastases, invasion beyond subcutaneous fat, and perineural invasion on microscopy. She explained that subtle signs like skin fixation can sometimes indicate deep invasion on exam when pathology is pending.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
January 28th 2025First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Read More
